Pharmacotherapy of osteoarthritis: where to start? An overview of current guidelines

The increasing global prevalence of osteoarthritis and the «rejuvenation» of the patient population require an increase in the number of patients with this pathology. According to the international guidelines EULAR, OARSI, ACR/AF and VA/DoD, nonsteroidal anti-inflammatory drugs are considered to be the «core» of the initial therapy of osteoarthritis. According to ACR/AF and VA/DoD experts, oral nonsteroidal anti-inflammatory drugs are the best choice; OARSI and VA/DoD representatives recommend starting treatment with oral non-selective nonsteroidal anti-inflammatory drugs. Diclofenac (Dicloberl Retard) can be considered the optimal non-selective nonsteroidal anti-inflammatory drug for the treatment of osteoarthritis due to the proven efficacy, safety and better pharmacological characteristics of the retard form.

References

1. GBD 2021 Osteoarthritis Collaborators (2023) Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol., 5(9): e508–e522. doi: 10.1016/S2665-9913(23)00163-7.
2. He Y., Jiang W., Wang W. (2024) Global burden of osteoarthritis in adults aged 30 to 44 years, 1990 to 2019: results from the Global Burden of Disease Study 2019. BMC Musculoskelet. Disord., 25(1): 303. doi: 10.1186/s12891-024-07442-w.
3. Коваленко В.М., Головач І.Ю., Борткевич О.П. та ін. (2020) Остеоартрит/Остеоартроз: клінічна настанова. Київ.
4. Біловол О.М., Князькова І.І. (2022) Остеоартрит. Ліки України (Medicine of Ukraine), 5–6: 261–262.
5. Kloppenburg M., Kroon F.P., Blanco F.J. (2019) 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann. Rheum. Dis., 78(1): 16–24. doi: 10.1136/annrheumdis-2018-213826.
6. Bannuru R.R., Osani M.C., Vaysbrot E.E. (2019) OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 27(11): 1578–1589. doi: 10.1016/j.joca.2019.06.011.
7. Kolasinski S.L., Neogi T., Hochberg M.C. (2020) Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol., 72(2): 220–233. doi: 10.1002/art.41142.
8. McAlindon T.E., Bannuru R.R., Sullivan M. (2014) OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage, 22(3): 363–388. doi: 10.1016/j.joca.2014.01.003.
9. Department of Veterans Affairs Department of Defense (2014) VA/DoD clinical practice guideline for the non-surgical management of hip & knee osteoarthritis; pp. 1–126. http://www.healthquality.va.gov/guidelines/CD/OA/VADoDOACPGFINAL090214.pdf Version 1.0.
10. van Walsem A., Pandhi S., Nixon R.M. (2015) Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res. Ther., 17(1): 66. doi: 10.1186/s13075-015-0554-0.
11. da Costa B.R., Pereira T.V., Saadat P. (2021) Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ, 375: n2321. doi: 10.1136/bmj.n2321.
12. Інструкція Диклоберл® Ретард. compendium.com.ua/dec/275098/.
13. Kołodziejczyk M.K., Kołodziejska J., Zgoda M.M. (2012) Właściwości technologiczne i farmakoterapeutyczne wybranych produktów leczniczych o modyfikowanym uwalnianiu soli sodowej diklofenaku [Technological and pharmacotherapeutic properties of selected drugs with modified release of diclofenac sodium]. Polim. Med., 42(2): 121–132.